Among the pro-angiogenic factors, Fibroblast Growth Factor 2 (FGF2) has been shown to play a relevant role in different tumor types, including MM [7,8,9], its blockade resulting in significant anti-tumor and anti-angiogenic activities [10,11]. Here, FGF2 is linked to Miyoshi myopathy.